Gyre Therapeutics Inc. (GYRE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gyre Therapeutics Inc. (GYRE) has a cash flow conversion efficiency ratio of 0.023x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.18 Million) by net assets ($136.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GYRE equity to assets ratio to measure how much of total assets are equity-financed.
Gyre Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Gyre Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Gyre Therapeutics Inc.'s earnings quality to evaluate the quality of earnings relative to operating cash generation.
Gyre Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gyre Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
WashTec AG
XETRA:WSU
|
0.092x |
|
Sawit Sumbermas Sarana Tbk
JK:SSMS
|
0.038x |
|
XiAn Catering Co Ltd
SHE:000721
|
-0.258x |
|
Eastern Polymer Group Public Company Limited
BK:EPG
|
0.054x |
|
Pepper Money Ltd
AU:PPM
|
-1.010x |
|
Bichamp Cutting Technology Hunan Co Ltd
SHE:002843
|
-0.025x |
|
Globalworth REIT
LSE:GWI
|
0.027x |
|
Henan Newland Pharmaceutical Co. Ltd. A
SHE:301277
|
N/A |
Annual Cash Flow Conversion Efficiency for Gyre Therapeutics Inc. (2004–2025)
The table below shows the annual cash flow conversion efficiency of Gyre Therapeutics Inc. from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Gyre Therapeutics Inc. worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $142.28 Million | $1.01 Million | 0.007x | +119.18% |
| 2024-12-31 | $98.40 Million | $-3.64 Million | -0.037x | -101.99% |
| 2023-12-31 | $13.95 Million | $25.89 Million | 1.856x | +1155.49% |
| 2022-12-31 | $72.22 Million | $10.68 Million | 0.148x | +107.25% |
| 2021-12-31 | $41.09 Million | $-83.75 Million | -2.038x | -181.68% |
| 2020-12-31 | $76.07 Million | $-55.05 Million | -0.724x | -13.39% |
| 2019-12-31 | $68.34 Million | $-43.61 Million | -0.638x | -168.10% |
| 2018-12-31 | $119.94 Million | $-28.55 Million | -0.238x | +63.26% |
| 2017-12-31 | $30.77 Million | $-19.94 Million | -0.648x | +43.63% |
| 2016-12-31 | $16.07 Million | $-18.47 Million | -1.149x | -88.93% |
| 2015-12-31 | $31.43 Million | $-19.12 Million | -0.608x | -92.45% |
| 2014-12-31 | $109.08 Million | $-34.48 Million | -0.316x | -4.78% |
| 2013-12-31 | $134.61 Million | $-40.61 Million | -0.302x | +17.38% |
| 2012-12-31 | $175.91 Million | $-64.24 Million | -0.365x | +23.98% |
| 2011-12-31 | $174.29 Million | $-83.72 Million | -0.480x | -131.90% |
| 2010-12-31 | $91.85 Million | $138.30 Million | 1.506x | +528.01% |
| 2009-12-31 | $68.99 Million | $-24.27 Million | -0.352x | +28.58% |
| 2008-12-31 | $57.37 Million | $-28.26 Million | -0.493x | -202.30% |
| 2007-12-31 | $51.58 Million | $24.84 Million | 0.482x | +416.38% |
| 2006-12-31 | $65.00 Million | $-9.89 Million | -0.152x | -194.22% |
| 2005-12-31 | $-162.48 Million | $-26.25 Million | 0.162x | -20.66% |
| 2004-12-31 | $-122.97 Million | $-25.04 Million | 0.204x | -- |
About Gyre Therapeutics Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in th… Read more